Dong-A ST said it signed a joint sales agreement with Yuyu Pharma on Monday for the peripheral circulation improvement drug Tanamine Tablet at the latter’s headquarters in Shindang-dong, Jung-gu, Seoul.

The two companies' senior managers, including Dong-A ST CEO Kim Min-young and Yuyu Pharma CEO Yu Won-sang, attended the signing ceremony.

Under the agreement, the two companies will jointly conduct promotional and marketing activities for Tanamin Tablet. They will conduct sales to general hospitals together. Besides general hospitals, Dong-A ST will be responsible for selling it to hospitals and clinics, while Yuyu will sell it to pharmacies.

Tanamin Tablet is a peripheral circulation enhancer made with EGb761, the original Ginkgo biloba dry extract developed and standardized by the Schwabe Group in Germany, as the active ingredient. It is effective in treating temperamental brain dysfunction accompanied by dementia symptoms, such as memory loss, dizziness, peripheral arterial circulation disorders (intermittent claudication), and vascular and degenerative tinnitus.

Tanamin’s active ingredient, EGb761, refers to the extract of ginkgo biloba 761. According to Dong-A ST, it is named after the standardized 761st sample, the best of many samples developed by the Schwabbe Group for superior ingredient ratios.

EGb761 is a raw pharmaceutical product standardized by identifying the pharmacological mechanisms of 57 ingredients through a 27-step patented extraction process, removing 26 harmful substances and standardizing the components with only 31 medicinal effects. Principal Component Analysis shows high batch-to-batch consistency, resulting in low variation in pharmacological activity.

"We have high expectations for the collaboration with Dong-A ST, which has the best sales and marketing manpower in Korea for oncology and hospitals and clinics," Yuyu Pharma CEO Yu said. "Ginkgo biloba dried extract, especially Tanamin with EGb761 as the active ingredient, published in more than 500 research papers, will become a representative product in the brain function improvement market."

Dong-A ST CEO Kim said, “The differentiation and superior effectiveness of Tanamin among ginkgo biloba extract formulations has been confirmed through prescriptions from many specialists, and the launch of a high-dose product last year has provided an opportunity to improve patient compliance further."

Kim added that through this co-marketing agreement, Dong-A ST and Yuyu Pharma will work together to promote Tanamin's superior effectiveness to many patients suffering from cognitive dysfunction.